TherapeuticsMD (TXMD) Net Margin (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly Net Margin came in at 17.84% in Q2 2026, down 4004.0% on a YoY basis from 0.46% in Q2 2025, and up 35.93% quarter-over-quarter from 13.12% in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) Net Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported Net Margin for 16 consecutive years, with 17.84% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 4004.0% year-over-year to 17.84%; the trailing twelve-month figure through Jun 2026 stood at 5.66% (up 587.0% YoY), and the FY2025 full-year result was 18.83%, up 10502.0% from the prior year.
- Net Margin advanced to 17.84% in Q2 2026 per TXMD's latest filing, from 13.12% in the prior quarter.
- Across five years, Net Margin topped out at 32092.24% in Q2 2022 and bottomed at 8097.46% in Q3 2022.
- Historically, Net Margin has averaged 454.3% across 5 years, with a median of 138.75% in 2024.
- The sharpest annual moves came in 2022 and 2023: Net Margin soared 3227768 bps in 2022, then slumped 3264464 bps in 2023.
- Over 5 years, Net Margin stood at 113.32% in 2022, then sank by 263 bps to 184.46% in 2023, then jumped by 134 bps to 62.37% in 2024, then tumbled by 205 bps to 65.73% in 2025, then jumped by 127 bps to 17.84% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 17.84%, 13.12%, and 65.73% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 22.65% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -1.58% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 25.56% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 2.96% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 13.90% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 17.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.84% |
| Mar 31, 2026 | 13.12% |
| Dec 31, 2025 | -65.73% |
| Sep 30, 2025 | 19.39% |
| Jun 30, 2025 | 57.88% |
| Mar 31, 2025 | -166.16% |
| Dec 31, 2024 | 62.37% |
| Sep 30, 2024 | -111.33% |
| Jun 30, 2024 | -493.59% |
| Mar 31, 2024 | -234.50% |
| Dec 31, 2023 | -184.46% |
| Sep 30, 2023 | -6,373.58% |
| Jun 30, 2023 | -552.40% |
| Mar 31, 2023 | -866.11% |
| Dec 31, 2022 | 113.32% |
| Sep 30, 2022 | -8,097.46% |
| Jun 30, 2022 | 32,092.24% |
| Mar 31, 2022 | -7,053.38% |
| Dec 31, 2021 | 268.50% |
| Sep 30, 2021 | -186.65% |